Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, ...
Fintel on MSN

LifeSci Capital initiates coverage of Ovid Therapeutics (OVID) with outperform recommendation

Fintel reports that on December 22, 2025, LifeSci Capital initiated coverage of Ovid Therapeutics (NasdaqCM:OVID) with a Outperform recommendation. Analyst Price Forecast Suggests 189.69% Upside As of ...
FierceBiotech

Ovid pauses phase 2 plans for ROCK2 inhibitor to mull mixed data from Recursion's rival drug

Ovid Therapeutics is pumping the brakes on a planned phase 2 trial for its ROCK2 inhibitor in a type of brain lesion while it considers any lessons to be learned from the mixed readout of Recursion’s ...
FierceBiotech

Ovid finds new focus in epilepsy but trims staff to extend cash runway

Ovid Therapeutics seems to have found its focus after a rough year: epilepsy. But the biotech will move toward this new direction with 20% fewer people at the company. The company announced a ...

Ovid’s Metamorphoses is all about mothers

Even if you haven’t heard of Ovid, you almost certainly know some of his stories. His most famous work, the Metamorphoses, is a Latin epic poem composed of hundreds of tales of mythical ...
Bow Doin Polar Bears

Reappraising Ovid: Professor Boyd Examines the Roman Poet’s Relationship with Homeric Tradition

Barbara Weiden Boyd is a big fan of Ovid, the Latin poet who died just about two thousand years ago. Apart from being a great humorist, she said, Ovid should be applauded for his brilliant re-working ...